The Scottish Medicines Consortium (SMC) has issued advice on seven different medicines, advising healthcare professionals as to whether they have been accepted for use, accepted for restricted use, or not recommended for use in NHS Scotland.
The medicines are listed under the following British National Formulary categories:
Central nervous system
- sufentanil citrate—not recommended for use.
- desmopressin—accepted for restricted use.
Malignant disease and immunosuppression
- carfilzomib—accepted for use*
- follitropin delta—not recommended for use
- venetoclax—accepted for use.*
Musculoskeletal and joint diseases
- canakinumab—not recommended for use.
- 5 aminolaevulinic acid—not recommended for use.
*This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of the appraised drug and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
The SMC aims to ensure that newly licensed medications representing good value for money are accepted for routine use in NHS Scotland as quickly as possible. It does this by bringing together a consortium that is made up of lead clinicians, pharmacists, and health economists, as well as representatives from health boards, the pharmaceutical industry, and the public.